MerckVaccines.com

Product Features


	Product Features
	Antibody Response
	Dosing Convenience
	List of Benefits
	Prescribing Information
	Storage and Handling
	Proper Handling Demo
	Select Safety Information

	ACIP Recommendations

	Disease Information

	Complimentary Resources

Select Another Product

PedvaxHIB elicits a higher antibody response after 2 doses^b,1

	Adapted from American Academy of Pediatrics (AAP), 1993.¹ Reproduced with permission from Pediatrics, Vol. 92, p 481. Copyright © 1993 by the AAP.
b	Compared to: HibTITER (a registered trademark of Wyeth Pharmaceuticals, Inc.), ActHIB (a registered trademark of Sanofi Pasteur Pharmaceuticals SA), and OmniHib (a registered trademark of GlaxoSmithKline Biologicals S.A.).
e	While the anti-PRP level associated with protection using conjugated vaccines has not yet been determined, the level of anti-PRP associated with protection in studies using bacterial polysaccharide immune globulin or nonconjugated PRP vaccines ranged from >0.15 mcg/mL to >1.0 mcg/mL.

PedvaxHIB is indicated for routine vaccination against invasive disease caused by Haemophilus influenzae type b in infants and children 2 to 71 months of age. PedvaxHIB should not be used in infants younger than 6 weeks of age.

Select safety information

PedvaxHIB is contraindicated in patients with hypersensitivity to any component of the vaccine. Persons who develop symptoms suggestive of hypersensitivity after an injection should not receive further injections of the vaccine.

The most frequently reported (>1%) adverse reactions, without regard to causality, were fever (>101°F), irritability, sleepiness, injection-site pain/soreness, injection-site erythema (<2.5 cm diameter), injection-site swelling/induration (<2.5 cm diameter), unusual high-pitched crying, prolonged crying (>4 hours), diarrhea, vomiting, crying, pain, otitis media, rash, and upper respiratory infection.

Before administering PedvaxHIB, please read the Prescribing Information.

Continue to Dosing convenience or List of benefits.

References: 1. American Academy of Pediatrics Committee on Infectious Diseases. Haemophilus influenzae type b conjugate vaccines: recommendations for immunization with recently and previously licensed vaccines. Pediatrics. 1993;92:480–488. 2. Data available on request from Merck & Co., Inc., Professional Services—DAP, WP1-27, PO Box 4, West Point, PA 19486-0004. Please specify information package 20703489(1)-PED.

PedvaxHIB is a registered trademark of Merck & Co., Inc.